Kersting S, Koomans HA, Hene RJ, Verdonck LF. Acute renal failure in the setting of bone marrow transplantation. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Hingorani SR, Guthrie K, Batchelder A, Schoch G, Aboulhosn N, Manchion J et al. Acute renal failure in hematopoietic cell transplantation. In conclusion, early AKI may portend a poor survival for allo-SCT recipients. Logistic regression analysis adjusted for the PS showed that early AKI was significantly associated with OS (odds ratio (95% confidence interval) 4.63 (1.15вЂ“21.4), P=0.031) but with neither NRM (1.25 (0.28вЂ“5.33), P=0.766) nor CKD (1.85 (0.41вЂ“8.60), P=0.422). The cumulative incidence of chronic kidney disease (CKD) over 2 years after SCT was 41.5% and 19.1% in early and late AKI, respectively ( P=0.048). Non-relapse mortality (NRM) was 39.1% and 7.0%, and overall survival (OS) was 56.5% and 90.9% in early and late AKI at 100 days after AKI, respectively ( P<0.001). The cumulative incidences of early and late AKI were 22.3% and 54.9%, respectively.

Propensity score (PS) for early AKI was calculated using a logistic regression model to reduce confounding effects related to differences in clinical background between the early and late AKI groups.

AKI prior to stem-cell engraftment was defined as early AKI and subsequently occurring AKI as late AKI. A prospective cohort study was performed to understand the significance of the onset timing in 103 allogeneic SCT (allo-SCT) recipients. Acute kidney injury (AKI) following stem-cell transplantation (SCT) contributes to a poor prognosis, yet its impact may vary depending on the timing of AKI onset.

Sct device updater window too small